Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > NanCogenics Invited to Present Novel Technology for the Targeted Delivery of Cancer Therapeutics at BioNanoMed 2013, the Fourth Annual International Conference

Abstract:
Officials at NanCogenics, Inc. announced today that Co-Founder Dr. Jim Klostergaard has been invited to present at the upcoming BioNanoMed 4th International Conference on Nanotechnology, Medicine and Biology, to be held March 13-15, in Krems, Austria. Dr. Klostergaard will speak about a paper titled "A Cancer Treatment Modality Based on the Tumor-Specific Localization of Cancer Therapeutics", which will discuss the application of the company's tumor targeting platform as a clinical procedure.

NanCogenics Invited to Present Novel Technology for the Targeted Delivery of Cancer Therapeutics at BioNanoMed 2013, the Fourth Annual International Conference

Houston, TX | Posted on March 6th, 2013

This prestigious three day congress will bring together academia, industry, governmental and non-governmental institutions to discuss current, emerging and future trends of the converging fields of Nanotechnology, Biotechnology and Medicine. The theme for BioNanoMed 2013 is Nanotechnology Enables Personalized Medicine which focuses on current and developing efforts to bring an individualized approach to cancer therapy.

The NanCogenics technology platform, as envisioned by Co-Founders, Dr. Klostergaard, Professor of Molecular and Cellular Oncology at the University of Texas M D Anderson Cancer Center (Houston, TX), and Charles Seeney, Managing Director of NewTech Development (Edmond, OK), enables the emerging trend to personalized medicine. The nanotechnology-based platform is based on designed therapeutic nano prodrug constructs that respond to external magnetic forces in targeting tumor sites, generating effective anti-tumor results without harm to normal tissue or organs, thereby substantially reducing the feared side effects and complications often attributed to chemotherapy. The Co-Founders believe that the advancement of this platform to the clinic will lead to significant improvements, not only in cancer chemotherapy, but also as a means of targeting a range of new cancer therapeutics now under development.

The Company's newly recruited President and CEO, states that "this conference provides a significant first step in our efforts to raise the awareness of the potential of magnetic localization, and the impact NanCogenics can have in the emerging field of nanomedicine". He further states that the Company is moving forward with funding mechanisms to support business objectives and anticipated future FDA IND filings.

####

About NanCogenics, Inc.
Overall, NanCogenics sees itself as a resource for enhanced and improved therapeutic performance, with more drug penetration occurring at the target site and less to normal tissue. The capacity to localize cytotoxic drugs in high concentrations at the tumor site will lead to more effective treatment regimens, greater patient compliance to therapy and improved outcomes, such as patient quality of life and survival rates.

Safe Harbor Statement

Certain statement included in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of products and services, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. The company's expectations regarding future revenues are dependent upon the ability to develop and supply products and services that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions are generally considered forward-looking statements. These statements reflect current expectations.

For more information, please click here

Contacts:
NCGI
Charles Seeney

Ph: 855.842.6771

Copyright © NanCogenics, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanoscale worms provide new route to nano-necklace structures March 29th, 2015

Solving molybdenum disulfide's 'thin' problem: Research team increases material's light emission by twelve times March 29th, 2015

A first glimpse inside a macroscopic quantum state March 28th, 2015

DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015

Nanomedicine

Novel nanoparticle therapy promotes wound healing March 27th, 2015

Graphene reduces wear of alumina ceramic March 26th, 2015

Application of Graphene Oxide in Body Implants in Iran March 26th, 2015

Nanorobotic agents open the blood-brain barrier, offering hope for new brain treatments March 25th, 2015

Announcements

Nanoscale worms provide new route to nano-necklace structures March 29th, 2015

Solving molybdenum disulfide's 'thin' problem: Research team increases material's light emission by twelve times March 29th, 2015

A first glimpse inside a macroscopic quantum state March 28th, 2015

DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015

Appointments/Promotions/New hires/Resignations/Deaths

Nanofilm Appoints Senior Sales/Marketing Executives: Don Tecco, Director of Optical Sales, North America and Rex Talbott, Business Director Optical Products March 23rd, 2015

KIT Increases Commitment in Asia: DAAD Funds Two New Projects: Strategic Partnerships with Chinese Universities and Communi-cation Technologies Network February 22nd, 2015

SouthWest Nanotechnologies CEO Dave Arthur Appointed to the Board of Affiliates of Rice University Professional Science Masterís Program February 13th, 2015

Nexeon Board Changes Announced January 29th, 2015

Events/Classes

State-of-the-art online system unveiled to pinpoint metrology software accuracy March 27th, 2015

LAMDAMAP 2015 hosted by the University March 26th, 2015

SUNY POLY CNSE to Host First Ever Northeast Semi Supply Conference (NESCO) Conference Will Connect New and Emerging Innovators in the Northeastern US and Canada with Industry Leaders and Strategic Investors to Discuss Future Growth Opportunities in NYS March 25th, 2015

NNI Publishes Workshop Report Assessing the Status of EHS Risk Science: Report examines progress three years after the release of the 2011 NNI EHS Research Strategy March 23rd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE